


(±)-N-3-Benzyl nirvanol**Chemical Properties**

CAS No. :	93879-40-4
Formula:	C ₁₈ H ₁₈ N ₂ O ₂
Molecular Weight:	294.35
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>

**Biological Description**

Description	(±)-N-3-Benzyl nirvanol is a racemic mixture of (+)-N-3-Benzyl nirvanol and (-)-N-3-Benzyl nirvanol. Both enantiomers are selective inhibitors of cytochrome P450, specifically inhibiting CYP2C19. (±)-N-3-Benzyl nirvanol also reduces plasma cholesterol levels in mice.
Targets(IC50)	Cytochromes P450

Solubility Information

Solubility	DMSO: 275 mg/mL (934.26 mM), Sonication is recommended. Methanol: Slightly soluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (33.97 mM), Solution. 10% DMSO+90% Saline: < 10 mg/mL (33.97 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3973 mL	16.9866 mL	33.9732 mL
5 mM	0.6795 mL	3.3973 mL	6.7946 mL
10 mM	0.3397 mL	1.6987 mL	3.3973 mL
50 mM	0.0679 mL	0.3397 mL	0.6795 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Suzuki H, et al. (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. *Drug Metab Dispos.* 2002;30(3):235-239.

Barnette DA, et al, Swamidass SJ, Miller GP. Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam. *Toxicol Lett.* 2021;338:10-20.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481